News | December 12, 2024
AbbVie completes acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
For people with relapsed or refractory diffuse large B-cell lymphoma
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
